Excitotoxic neurodegeneration is associated with a focal decrease in metabotropic glutamate receptor type 5 availability: an in vivo PET imaging study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 09 2019
Historique:
received: 21 03 2019
accepted: 23 08 2019
entrez: 11 9 2019
pubmed: 11 9 2019
medline: 28 10 2020
Statut: epublish

Résumé

Metabotropic glutamate receptors (mGluRs) have been proposed as promising therapeutic targets to correct the dysregulated glutamate signaling, associated with neurodegenerative pathologies. Of all mGluR subtypes, especially mGluR5 acts as a modulator of glutamate-induced excitotoxicity. To study the behavior of mGluR5 following localized excitotoxicity, we utilised a pharmacological model that portrays exacerbated neuronal glutamate release, mediated by the endogenous excitotoxin quinolinic acid (QA). Using longitudinal positron emission tomography (PET) with [

Identifiants

pubmed: 31501497
doi: 10.1038/s41598-019-49356-x
pii: 10.1038/s41598-019-49356-x
pmc: PMC6733799
doi:

Substances chimiques

Biomarkers 0
Grm5 protein, rat 0
Receptor, Metabotropic Glutamate 5 0
Glutamic Acid 3KX376GY7L

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12916

Références

Front Aging Neurosci. 2018 Sep 11;10:262
pubmed: 30271338
Annu Rev Pharmacol Toxicol. 1997;37:205-37
pubmed: 9131252
Brain Res. 1986 Apr 23;371(2):267-77
pubmed: 2938667
Br J Pharmacol. 2000 Dec;131(7):1429-37
pubmed: 11090117
Neurochem Res. 2015 Jun;40(6):1121-32
pubmed: 25846008
Brain Res Brain Res Rev. 1995 Jan;20(1):91-127
pubmed: 7711769
Neuroscience. 2017 Jul 25;356:52-63
pubmed: 28527955
J Biol Chem. 2009 Jun 5;284(23):15629-39
pubmed: 19364772
Gene Ther. 2008 Jul;15(13):966-77
pubmed: 18323792
Synapse. 1989;3(1):38-47
pubmed: 2563916
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):704-15
pubmed: 18080815
Neuron. 1988 Oct;1(8):623-34
pubmed: 2908446
Neurobiol Aging. 2018 Jan;61:82-92
pubmed: 29055799
Mov Disord. 2013 Nov;28(13):1838-46
pubmed: 23853029
Neuropsychopharmacology. 2018 Feb;43(3):503-512
pubmed: 28816242
J Pharmacol Exp Ther. 2001 Jan;296(1):41-7
pubmed: 11123360
J Neuroimmunol. 2007 Sep;189(1-2):23-30
pubmed: 17628702
J Nucl Med. 2006 Nov;47(11):1858-66
pubmed: 17079820
J Biol Chem. 2005 Oct 14;280(41):34840-8
pubmed: 16091361
Neurology. 2011 May 17;76(20):1750-7
pubmed: 21576693
Reprod Toxicol. 2012 Sep;34(2):192-203
pubmed: 22664268
Molecules. 2017 Apr 23;22(4):
pubmed: 28441750
BMC Neurosci. 2010 Aug 09;11:92
pubmed: 20691122
Neurobiol Aging. 2015 Mar;36(3):1543-58
pubmed: 25599874
PLoS One. 2013 Aug 05;8(8):e70415
pubmed: 23940572
Neuroscience. 2014 Dec 5;281:24-34
pubmed: 25250840
Neuropharmacology. 2017 Mar 15;115:180-192
pubmed: 27140693
Synapse. 2005 Jun 15;56(4):205-16
pubmed: 15803497
Neurobiol Dis. 2015 Jan;73:163-73
pubmed: 25160573
Exp Neurol. 1989 Jul;105(1):45-53
pubmed: 2526022
J Nucl Med. 2013 Mar;54(3):388-96
pubmed: 23404089
Neuron. 2011 Apr 28;70(2):339-51
pubmed: 21521618
J Nucl Med. 2018 Nov;59(11):1722-1727
pubmed: 29794227
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Adv Neurol. 1986;44:857-77
pubmed: 3706027
Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2354-63
pubmed: 20680268
Eur J Neurosci. 2000 Jul;12(7):2333-44
pubmed: 10947812
J Neurosci. 1995 May;15(5 Pt 2):3775-87
pubmed: 7751945
J Nucl Med. 2015 Dec;56(12):1954-9
pubmed: 26405172
Adv Pharmacol. 2018;82:293-323
pubmed: 29413525
J Vis Exp. 2017 Aug 30;(126):
pubmed: 28892027
J Comp Neurol. 1995 May 8;355(3):455-69
pubmed: 7636025
Nat Neurosci. 2017 Nov;20(11):1569-1579
pubmed: 28945221
Ann Neurol. 1998 Sep;44(3 Suppl 1):S110-4
pubmed: 9749581
Neurosci Lett. 2002 Feb 1;318(3):137-40
pubmed: 11803118
Synapse. 2007 Dec;61(12):951-61
pubmed: 17787003
Ann Neurol. 2013 May;73(5):667-78
pubmed: 23494575
Mol Brain. 2015 Apr 10;8:24
pubmed: 25885370
Nucl Med Biol. 2002 Apr;29(3):307-16
pubmed: 11929700
Front Behav Neurosci. 2014 Jul 22;8:252
pubmed: 25100962

Auteurs

Melissa Crabbé (M)

Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium. crabbe.melissa@outlook.com.
MoSAIC - Molecular Small Animal Imaging Centre, KU Leuven, Leuven, Belgium. crabbe.melissa@outlook.com.

Nina Dirkx (N)

Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
MoSAIC - Molecular Small Animal Imaging Centre, KU Leuven, Leuven, Belgium.

Cindy Casteels (C)

Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
MoSAIC - Molecular Small Animal Imaging Centre, KU Leuven, Leuven, Belgium.

Koen Van Laere (KV)

Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
MoSAIC - Molecular Small Animal Imaging Centre, KU Leuven, Leuven, Belgium.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH